SXDPEX:SW:SW-iShares STOXX Europe 600 Health Care UCITS ETF (DE) EUR (EUR)

ETF | Others |

Last Closing

USD 116.14

Change

0.00 (0.00)%

Market Cap

USD 0.44B

Volume

421.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

-0.12 (-0.84%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.18 (-0.80%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.22 (-0.74%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.05 (-0.15%)

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-50.00 (-0.87%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-9.80 (-0.55%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-14.50 (-0.59%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

-0.47 (-0.57%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

-0.46 (-0.39%)

USD 130,595.12B

ETFs Containing SXDPEX:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.92% 78% C+ 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.92% 78% C+ 76% C+
Trailing 12 Months  
Capital Gain 5.52% 36% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.52% 33% F 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.84% 47% F 49% F
Dividend Return 4.84% 47% F 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.61% 71% C- 75% C
Risk Adjusted Return 86.20% 64% D 68% D+
Market Capitalization 0.44B 53% F 49% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.